Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company committed to
the development and commercialization of innovative anti-cancer therapeutics.

FOLOTYN is the first and only drug approved in the U.S. for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. This indication is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated. Allos is also developing FOLOTYN in other potential indications. Allos retains exclusive worldwide rights to FOLOTYN for all indications. The Company is headquartered in Westminster, Colorado.